Motto dnia

Zdrowie to stan, o którym medycyna nie ma nic do powiedzenia.

W.H. Auden

obrazek winietyobrazek winiety

Publikacje naukowe

Neoadjuwantowa chemioterapia sama lub w połączeniu z hipertermią regionalną w leczeniu miejscowych mięsaków tkanek miękkich wysokiego ryzyka: randomizowane wieloośrodkowe badanie kliniczne 3 fazy

tytuł oryg.: Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study
Wydawnictwo: The Lancet
Autor główny: Rolf D Issels
Pozostali autorzy: Rolf D Issels*, Lars H Lindner*, Jaap Verweij, Peter Wust, Peter Reichardt, Baard-Christian Schem, Sultan Abdel-Rahman, Soeren Daugaard, Christoph Salat, Clemens-Martin Wendtner, Zeljko Vujaskovic, Rüdiger Wessalowski, Karl-Walter Jauch, Hans Roland Dürr, Ferdinand Ploner, Andrea Baur-Melnyk, Ulrich Mansmann, Wolfgang Hiddemann, Jean-Yves Blay, Peter Hohenberger
Data: 2016-04-29

DOI: 10.1016/S1470-2045(10)70071-1

Język publikacji: angielski

Klasa publikacji: Badanie kliniczne

Randomizowane: TAK

Wieloośrodkowe: TAK

Faza badania klinicznego: 3

Liczba pacjentów: 341

Rodzaj HT: LRHT RF

Rodzaj HT opis: HT miejscowa, głęboka, fale radiowe

Aparatura: BSD-2000

Jednostka chorobowa: Mięsaki tkanki miękkiej

Symbol Jednostki chorobowej: LHRSTS

Stage: II-III

Typ skojarzenia HT stosowany w badaniu: HT+CT

Rodzaj CT: EIA (etoposide, ifosfamide, doxorubicin)

Abstract. Background: The optimum treatment for high-risk soft-tissue sarcoma (STS) in adults is unclear. Regional hyperthermia concentrates the action of chemotherapy within the heated tumour region. Phase 2 studies have shown that chemotherapy with regional hyperthermia improves local control compared with chemotherapy alone. We designed a parallelgroup randomised controlled trial to assess the safety and efficacy of regional hyperthermia with chemotherapy.
Methods: Patients were recruited to the trial between July 21, 1997, and November 30, 2006, at nine centres in Europe and North America. Patients with localised high-risk STS (≥5 cm, Fédération Nationale des Centres de Lutte Contre le Cancer [FNCLCC] grade 2 or 3, deep to the fascia) were randomly assigned to receive either neo-adjuvant chemotherapy consisting of etoposide, ifosfamide, and doxorubicin (EIA) alone, or combined with regional hyperthermia (EIA plus regional hyperthermia) in addition to local therapy. Local progression-free survival (LPFS) was the primary endpoint. Efficacy analyses were done by intention to treat. This trial is registered with, number NCT 00003052.
Findings: 341 patients were enrolled, with 169 randomly assigned to EIA plus regional hyperthermia and 172 to EIA alone. All patients were included in the analysis of the primary endpoint, and 332 patients who received at least one cycle of chemotherapy were included in the safety analysis. After a median follow-up of 34 months (IQR 20–67), 132 patients had local progression (56 EIA plus regional hyperthermia vs 76 EIA). Patients were more likely to experience local progression or death in the EIA-alone group compared with the EIA plus regional hyperthermia group (relative hazard [RH] 0·58, 95% CI 0·41–0·83; p=0·003), with an absolute diff erence in LPFS at 2 years of 15% (95% CI 6–26; 76% EIA plus regional hyperthermia vs 61% EIA). For disease-free survival the relative hazard was 0·70 (95% CI 0·54–0·92, p=0·011) for EIA plus regional hyperthermia compared with EIA alone. The treatment response rate in the group that received regional hyperthermia was 28·8%, compared with 12·7% in the group who received chemotherapy alone (p=0·002). In a prespecified pre-protocol analysis of patients who completed EIA plus regional hyperthermia induction therapy compared with those who completed EIA alone, overall survival was better in the combined therapy group (HR 0·66, 95% CI 0·45–0·98, p=0·038). Leucopenia (grade 3 or 4) was more frequent in the EIA plus regional hyperthermia group compared with the EIA-alone group (128 of 165 vs 106 of 167, p=0·005). Hyperthermia-related adverse events were pain, bolus pressure, and skin burn, which were mild to moderate in 66 (40·5%), 43 (26·4%), and 29 patients (17·8%), and severe in seven (4·3%), eight (4·9%), and one patient (0·6%), respectively. Two deaths were attributable to treatment in the combined treatment group, and one death was attributable to treatment in the EIA-alone group.
Interpretation: To our knowledge, this is the first randomised phase 3 trial to show that regional hyperthermia increases the benefit of chemotherapy. Adding regional hyperthermia to chemotherapy is a new effective treatment strategy for patients with high-risk STS, including STS with an abdominal or retroperitoneal location.
Funding: Deutsche Krebshilfe, Helmholtz Association (HGF), European Organisation of Research and Treatment of Cancer (EORTC), European Society for Hyperthermic Oncology (ESHO), and US National Institute of Health (NIH).

Potrzebujesz więcej danych o artykule? Skontaktuj się z PTHO droga mailową.